Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Bremelanotide (Vyleesi) Peptide
Melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women.
What is Bremelanotide (Vyleesi)?
Bremelanotide (Vyleesi) is a melanocortin agonist · sexual health peptide studied for acquired, generalized hypoactive sexual desire disorder (hsdd) in premenopausal women. Below is an educational overview of Bremelanotide (Vyleesi) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Vyleesi
Acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
An on-demand injection that activates brain pathways tied to sexual desire. Used as needed before intimacy, not daily.
- •Nausea
- •Flushing
- •Headache
- •Vomiting
- •Cough
- •Transient increases in blood pressure
- •Focal hyperpigmentation (skin darkening)
- •Uncontrolled hypertension
- •Known cardiovascular disease
- •Pregnancy
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Bremelanotide (Vyleesi) Mechanism of Action
Cyclic 7-amino-acid synthetic analog of α-MSH that activates melanocortin receptors (primarily MC4R) in the CNS, modulating sexual desire pathways.
Bremelanotide (Vyleesi) Research Areas & Benefits
Bremelanotide (Vyleesi) Dosage & Common Research Protocols
1.75 mg SC at least 45 minutes before anticipated sexual activity (max 1 dose/24h, 8/month).
Protocols summarized for educational reference from published research. Not dosing guidance.
Bremelanotide (Vyleesi) Studies & Cited Research
RECONNECT trials
Improved desire and reduced distress vs placebo in premenopausal HSDD.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Bremelanotide (Vyleesi) Side Effects & Safety Considerations
- •FDA-approved.
- •Nausea, flushing, transient BP elevation common.
Common questions about Bremelanotide (Vyleesi)
More Hormonal peptides · See all 14
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.